Breaking News

Janssen Acquires Hep C Treatment from GSK

To initiate Phase II studies for combination therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has acquired all rights to the investigational compound GSK2336805 from an affiliate of GlaxoSmithKline. GSK2336805 is an NS5a replication complex inhibitor currently in Phase II development for the treatment of chronic hepatitis C. Financial details were not disclosed.   Janssen plans to initiate Phase II studies to evaluate GSK2336805 in interferon-free combinations with the investigational protease inhibitor simeprevir, TMC435 an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters